The company's history can be traced back to 1969, formerly known as the Jiangxi branch of the Shanghai Institute of Biological Products of the Ministry of Health. After more than 50 years of development and accumulation, it has formed a profound foundation in biopharmaceutical technology and industry. In 2002, the limited liability company was restructured, and in December 2017, a shareholding system reform was implemented. With the continuous efforts of several generations of scientific research and management teams, it has now developed into a national high-tech leading enterprise in the field of antitoxin and immune serum biological products in China.

      Guided by the national biopharmaceutical industry development strategy, the company has established a strategic layout system of "three bases and two centers" covering the whole country, with eight wholly-owned subsidiaries under its jurisdiction, forming a complete ecological chain of the biopharmaceutical industry. We have established a specialized human pharmaceutical product base in Jiangxi, focusing on the research and manufacturing of antitoxin and immune serum products; Establish a horse breeding and immunization horse plasma collection base in Gansu Province to ensure the supply of core raw materials from the source; Build the largest and highest standard animal medicine product base in Inner Mongolia, effectively filling the industry gap; Establishing a cutting-edge drug research and development center in Shenzhen, integrating industry, academia, research, and medical applications, and promoting biotechnology innovation; Build a pharmaceutical research and development technology service platform in Hainan Province to achieve efficient integration of high-quality global resources.

      The company adheres to the vertical integration development model of the entire industry chain and has established a closed-loop management system covering the entire process of raw material collection, research and development production, and terminal delivery. By relying on strict quality control standards and digital monitoring systems, we have achieved independent and controllable control of core raw materials, optimized production cost management, and achieved industry-leading product quality stability. With the advantage of a complete industrial chain synergy, we continue to provide safe, efficient, and stable biological products to global customers, demonstrating strong industrial competitiveness and sustainable development capabilities in international market competition.

      The company's main business covers the research and development of biological products, animal breeding for experimental use, and biotechnology promotion services. Its core products include tetanus antitoxin (immunoglobulin), which has won multiple honors such as the "Gold Award of the 7th ASEAN Traditional Chinese Medicine Academic Conference" and the "Excellent New Product of Jiangxi Province". It has also been awarded the title of "Jiangxi Province Ganchu Boutique and Jiangxi Famous Brand". The company has outstanding production and sales capabilities, and its products have been exported to more than 30 countries and regions, serving over one billion users worldwide. Its market influence and brand reputation continue to improve.

      The company attaches great importance to technological innovation and talent cultivation, and has established multiple provincial-level and above scientific research platforms such as the "Provincial Enterprise Technology Center" and the "Jiangxi Province Biological Immune Antibody Drug Research and Development Center". It has also set up "Jiangxi Province Postdoctoral Innovation Practice Base", "Provincial and Municipal Hai Zhi Plan Workstation", and "Municipal Expert Workstation". By implementing the strategy of strengthening enterprises through talent, we have gathered a group of high-quality management, technical, and R&D talents, equipped with advanced production and R&D equipment that is specialized, digital, and intelligent, forming a strong research and innovation capability and the ability to transform scientific and technological achievements.

      The company has won numerous awards in its development process and has been recognized as a "National High tech Enterprise". It has also been honored with titles such as "Advanced Collective in National Comparative Work", "Jiangxi Province Specialized and Innovative Enterprise", and "Jiangxi Province Specialized Small Giant Enterprise". At the same time, the company actively fulfills its social responsibilities and has been awarded titles such as "Excellent Enterprise in Jiangxi Province, Provincial Private Science and Technology Enterprise, Provincial Advanced Grassroots Party Organization, and Jiangxi Worker Pioneer" multiple times. It has been continuously recognized as one of the "Top Ten Private Science and Technology Enterprises, Civilized Units, and Large Taxpayers in Ji'an City" for many years.

      Looking towards the future, the company will always uphold the mission of "making high-quality drugs for people around the world", with the strategic goal of building a "global serum base", continuously introducing international advanced technology, promoting process innovation and product upgrading. By implementing major projects to drive the strategy, accelerating the layout of the capital market, further enhancing the core competitiveness and international influence of enterprises, and making greater contributions to promoting the high-quality development of China's biopharmaceutical industry and safeguarding the lives and health of the people.